<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content

TumorGraft3D™ Ex Vivo Platform

Our TumorGraft3D platform supports selected ex vivo studies using low-passage, PDX-derived 3D tumor models. Designed for cohort comparison, asset benchmarking, and mechanism-focused questions helping teams generate earlier comparative and translational insights before moving into more resource-intensive in vivo work.

Clinically Relevant 3D Tumor Models for Rapid, Translational Insights.

Cell lines and expanded organoid systems can lack tumor complexity and heterogeneity, while in vivo studies are resource-intensive and lower throughput. TumorGraft3D is intended to provide a practical bridge between speed, scale, and clinically relevant tumor biology.

 

Clinically Relevant, PDX-Derived Biology

Low-passage 3D tumor models derived from PDX lineages established from clinically relevant patient tumors, including advanced, metastatic, and often pretreated disease.

Matrix-Free Assay Format

No added extra-cellular matrix (ECM), reducing potential drug-binding effects and matrix-associated autofluorescence for clearer assay interpretation.

Translational Bridge to In Vivo

Built from the same PDX-derived model lineage used in in vivo studies, supporting focused follow-up when in vivo biology is needed.



Practical Study Startup

Banked models give teams a practical path to study initiation, with readiness, timelines, and design requirements validated model-by-model.


Scale of the TumorGraft3D Platform

1500
+
Patient-derived xenograft (PDX) models
300
+
TumorGraft3D models and growing
25
+
Tumor indications with treatment histories

Applications

TumorGraft3D is best suited for defined translational questions where model selection, controls, assay timing, and readouts match the scientific decision.

We can support small molecules, biologics, ADCs, selected immune-mediated questions, and radiation-based agents when the model and assay fit are confirmed

organoid histo
Compare defined assets, constructs, or regimens in clinically relevant 3D tumor models selected to match the biological question, indication, or biomarker of interest. TumorGraft3D can provide comparative signals for ranking, cohort profiling, and go/no-go decisions when the assay design is fit for purpose.
Support dose-response analysis, IC50 generation, and rank-ordering for compatible models and assay windows.
Matrix-free format avoids added ECM, reducing potential drug-binding effects and supporting clearer imaging and assay interpretation.
Low-passage, heterogeneous models can support evaluation of target expression and treatment response when qualified readouts are available.
Best suited for indication-specific, biomarker-defined, or target-driven screens with appropriate controls and cohort size.

The Questions TumorGraft3D Aims to Answer

  • How does response vary across a biologically defined cohort?
  • Which asset, construct, or regimen looks strongest in the same tumor context?
  • Is the response target-dependent, and what controls are needed to separate target, payload, isotype, or construct effects?
  • Does immune context materially change apparent activity versus monoculture?
  • Can the study generate a biologically grounded hypothesis for why some models respond and others do not?
  • Does response track with a genotype-defined subgroup?

A Partner in Translational Oncology

Champions’ scientists work as partners in model selection, assay design, controls, and endpoint selection, helping clients generate the right data for the decision at hand. Projects are scoped to confirm model readiness, assay fit, and a practical path to downstream interpretation.

Every study starts with the scientific decision: what comparison needs to be made, what biology must be represented, and what readout package is needed to answer it credibly.

Identify the Best Ex Vivo Platform for Your Project

Platforms_010
 
Evaluate defined assets, cohorts, and mechanism-focused questions in Champions’ matrix-free, multiclonal 3D ex vivo cultures established from PDX-derived tumor models.
Platforms_08
 
Assess immune-mediated effects, tumor-immune interactions, and engineered cell therapy questions in qualified models using study designs scoped with Champions’ scientific team.
Platforms_09
 
Access a large bank of highly characterized primary, never-passaged hematological models from leukemia, lymphoma, and myeloma patients.
Interested in Learning More?

Download our Capabilities Overview 

capabilitie-overview-2026
Featured Posters

Get in touch

Fill out the form to learn more about our platforms and what they can do for you.
Frequently Asked Questions
What are PDX derived organoids (PDXOs)?
They are three-dimensional tumor models generated from low passage PDX tumors, preserving the genetic complexity and treatment history of real patient tumors.
How do Champions’ organoids differ from conventional PDOs?
Unlike PDOs that rely on dissociated tumor cells and Matrigel, Champions’ organoids are Matrigel free, assay ready, and retain more clinically relevant features.
How quickly can a study start using Champions’ organoids?
Because the models are cryopreserved as assay ready vials, studies can typically begin within ~10 days of protocol finalization.
What types of cancers are available in the organoid platform?
The platform covers a wide range of indications, including hard-to-grow tumors such as prostate cancer, GBM, and melanoma.
Can these organoids be used for high throughput screening?
Yes. Champions’ organoids support screening across dozens of models in parallel, producing high quality dose–response data much faster than traditional systems.
Are the organoids suitable for mechanistic or biomarker studies?
Absolutely. They can be integrated with RNA-seq, WES, flow cytometry, cytokine profiling, and drug-seq for deeper mechanistic insights.
Do the organoids support immune co-culture?
Yes. Autologous or allogeneic immune cells can be introduced to evaluate immune response, target engagement, and tumor killing.
Why does being Matrigel free matter?
Avoiding Matrigel prevents drug diffusion issues and imaging artifacts, resulting in more consistent drug exposure and clearer imaging outputs.
How are Champions’ organoids stored and prepared?
They are cryopreserved as assay ready vials. On the day of the study, they are thawed and seeded into Ubottom plates to form three-dimensional structures.
How do Champions’ organoids help bridge to in vivo or clinical studies?
Because they retain real patient tumor features, they provide population level insights that closely align with in vivo and clinical outcomes.
Can these organoids be used for radiopharmaceutical research?
Yes. Their longer viability compared to cell lines makes them ideal for extended studies required for radiopharmaceutical testing.
Are the models customizable for specific study needs?
Yes. Champions’ scientists work closely with clients to design studies that address specific research questions, indications, or endpoints.
How do Champions ensure data quality and reproducibility?
All models are deeply characterized, and studies are run in consultation with experienced scientists to ensure rigorous, reproducible results.